MorphoSys AG has completed sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as  all  shares  of  the  subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.

Jens Holstein, Chief Financial Officer of MorphoSys AG said, “We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100 per cent of its attention to building value in its core therapeutics business.”

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry.